Future Perspectives – so that patients can live longer, better and more productive lives
Celgene is a global biopharmaceutical company with a German presence in Munich since 2006 which currently employs a staff of about 300 people. The roots of the company lie in the field of rare diseases in hematology. But the portfolio has grown steadily over the last years including now treatments for hematologic, oncological and severe immune and inflammatory diseases with a high unmet medical need. The vision is set: to help those affected to participate in societal life as long as possible and ensure that their lives remain worth living despite their condition.
Celgene is a global biopharmaceutical company with a German presence in Munich since 2006 which currently employs a staff of about 300 people. The roots of the company lie in the field of rare diseases in hematology. But the portfolio has grown steadily over the last years including now treatments for hematologic, oncological and severe immune and inflammatory diseases with a high unmet medical need. The vision is set: to help those affected to participate in societal life as long as possible and ensure that their lives remain worth living despite their condition.
Celgene sponsors the symposium with a contribution of 30.000 Euro.
TESARO
TESARO is a biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. We see new possibilities to responsibly develop and commercialize innovative treatments where others may not. Relationships are vital to the success of our business, and we are committed to being a trusted partner to the cancer community. For further information please visit www.tesarobio.com.
TESARO is a biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. We see new possibilities to responsibly develop and commercialize innovative treatments where others may not. Relationships are vital to the success of our business, and we are committed to being a trusted partner to the cancer community. For further information please visit www.tesarobio.com.
TESARO sponsors the symposium with a contribution of 30.000 Euro.
AbbVie in Oncology – Jointly Pushing Boundaries
AbbVie’s oncology research is focused on the discovery and development of targeted therapies that work against the processes cancers need to survive. By investing in new technologies and approaches, the company is working on the development of innovative, groundbreaking treatments for some of the most difficult-to-treat cancers. AbbVie’s vision in oncology is to jointly push the boundaries in cancer treatment. AbbVie has set itself the challenge of delivering solutions for severe diseases that to date could not be treated adequately, thereby driving innovation. AbbVie’s pipeline includes multiple new molecules in clinical trials being studied in more than 20 different cancers and tumor types.
AbbVie’s oncology research is focused on the discovery and development of targeted therapies that work against the processes cancers need to survive. By investing in new technologies and approaches, the company is working on the development of innovative, groundbreaking treatments for some of the most difficult-to-treat cancers. AbbVie’s vision in oncology is to jointly push the boundaries in cancer treatment. AbbVie has set itself the challenge of delivering solutions for severe diseases that to date could not be treated adequately, thereby driving innovation. AbbVie’s pipeline includes multiple new molecules in clinical trials being studied in more than 20 different cancers and tumor types.
AbbVie sponsors the symposium with a contribution of 10.000 Euro.
Amgen
Amgen is a world-leading independent biotechnology company with nearly 20,000 employees in almost 100 countries worldwide for nearly 40 years. In Germany, we work every day at three locations with over 750 employees to serve patients. Every year, millions of patients worldwide with severe or rare diseases benefit from our therapies. Our drugs are used in nephrology, cardiology, hematology, oncology, bone health and chronic inflammatory diseases. In addition to original preparations, our portfolio also includes biosimilars. We have a diverse pipeline.
Amgen is a world-leading independent biotechnology company with nearly 20,000 employees in almost 100 countries worldwide for nearly 40 years. In Germany, we work every day at three locations with over 750 employees to serve patients. Every year, millions of patients worldwide with severe or rare diseases benefit from our therapies. Our drugs are used in nephrology, cardiology, hematology, oncology, bone health and chronic inflammatory diseases. In addition to original preparations, our portfolio also includes biosimilars. We have a diverse pipeline.
Amgen sponsors the symposium with a contribution of 10.000 Euro.
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Thus, the treatment of cancer remains a critical focus of our work – and our immuno-oncology portfolio plays a key role. Beyond oncology, we have achieved progress in areas such as immunoscience, cardiovascular and fibrosis where we believe we have an opportunity to make a meaningful difference for patients. Each day, our employees around the world work together for patients – it drives everything we do.
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Thus, the treatment of cancer remains a critical focus of our work – and our immuno-oncology portfolio plays a key role. Beyond oncology, we have achieved progress in areas such as immunoscience, cardiovascular and fibrosis where we believe we have an opportunity to make a meaningful difference for patients. Each day, our employees around the world work together for patients – it drives everything we do.
BMS sponsors the symposium with a contribution of 10.000 Euro.
Hexal
Sandoz is a global leader in generic pharmaceuticals and biosimilars. As part of the Novartis Group, our goal is to find new ways to improve and extend people’s lives. We are making a social contribution to supporting the growing need for healthcare through groundbreaking, novel approaches and to providing access to quality medicine to people around the world. As part of the Sandoz Group in Germany, the product brand Hexal is responsible for supplying patients with modern medicines as well as complex, innovative pharmaceuticals in Germany.
Sandoz is a global leader in generic pharmaceuticals and biosimilars. As part of the Novartis Group, our goal is to find new ways to improve and extend people’s lives. We are making a social contribution to supporting the growing need for healthcare through groundbreaking, novel approaches and to providing access to quality medicine to people around the world. As part of the Sandoz Group in Germany, the product brand Hexal is responsible for supplying patients with modern medicines as well as complex, innovative pharmaceuticals in Germany.
Hexal sponsors the symposium with a contribution of 10.000 Euro.
Roche Foundation Medicine, Inc.
Foundation Medicine works with one of the largest databases of genetic profiles of over 200,000 patient profiles, collaborates with more than 30 partners in the biopharmaceutical industry, and has published over 200 publications. The service portfolio includes: Foundation One CDx for the profiling of solid tumors, FoundationOne Liquid – the Liquid Biopsy from Foundation Medicine and FoundationOne Heme for sarcomas and haematological diseases. Since 2017, the FoundationOne CDx outpatient test in DE has been reimbursable for patients with statutory health insurance.
Foundation Medicine works with one of the largest databases of genetic profiles of over 200,000 patient profiles, collaborates with more than 30 partners in the biopharmaceutical industry, and has published over 200 publications. The service portfolio includes: Foundation One CDx for the profiling of solid tumors, FoundationOne Liquid – the Liquid Biopsy from Foundation Medicine and FoundationOne Heme for sarcomas and haematological diseases. Since 2017, the FoundationOne CDx outpatient test in DE has been reimbursable for patients with statutory health insurance.
Roche sponsors the symposium with a contribution of 10.000 Euro.
About MSD
For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships.
For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships.
MSD sponsors the symposium with a contribution of 5.000 Euro.
Are you interested in sponsoring the MOLIT Symposium yourself? Contact us.